A Phase 4 interventional study of Tranexamic acid and Saline in Injection Site Bruising, sponsored by University of Wisconsin, Madison. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-26.
Sponsored by University of Wisconsin, Madison · Phase 4, Interventional, and Supportive care
Among 198 studies in Patient Satisfaction with a site in United States — 30 open to participants now, 35 under way, none of them phase 3. Patient Satisfaction · United States.
Among the 198 studies in Patient Satisfaction with a site in United States, this one is the 152nd largest by enrollment of the 162 interventional ones that give a count, is one of 15 that started in 2022, is one of 18 in phase 4, and was the 108th registered.
877 studies on the registry are indexed under Patient Satisfaction; 202 are open to participants now.
Browse Patient Satisfaction studies →30 of the 198 studies in Patient Satisfaction with a site in United States are open now. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
University of Chicago · Sites in United States
University of California, Los Angeles · Sites in United States
Children's National Research Institute · Sites in United States
VA Office of Research and Development · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 99 Patient Satisfaction studies recruiting now, 61 (62%) set no upper age limit and 30 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 1 · Phase 4 18
First in 1999; this study’s year is marked. 15 started in 2022.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 100 across the 162 interventional studies, 160 across the 36 observational. Of the 146 that completed or were terminated, 42 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 198 have an industry lead sponsor. The 10 most frequent:
University of Wisconsin, Madison is the lead sponsor of 1,188 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
University of Wisconsin, Madison has 1 study filed under Patient Satisfaction — fewer than ten, so there is no comparison to draw.
17 of the studies in Patient Satisfaction with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06799052Boston Medical CenterCervical Preparation for Same-Day Dilation & Evacuation | 2026-12 |
| NCT06790043Albany Medical CollegeImpact of Patient Selected Visual Art in the Hospital Room During Antepartum Admission on Hospital Satisfaction Scores and Patient Experience | 2026-12 |
| NCT06975033University of California, San FranciscoEducational Discharge Video Impact on Post-Operative Healthcare Utilization After HoLEP | 2026-12-01 |
| NCT07715591University of California, Los AngelesRandomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery | 2026-12-31 |
| NCT07821476Gebauer CompanyIs Pain Ease (New Formula) Safe and Effective in Reducing Pain Associated With Peripheral Intravenous Cannulation (PIV)? | 2027-01 |
Among the 198 studies in Patient Satisfaction with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall purpose of this study is to evaluate the safety and efficacy of co-administration of tranexamic acid (TXA) with hyaluronic acid (HA) in reducing swelling, bruising and pain after facial injection. This will be done by comparing HA to HA+TXA in participants undergoing facial filler injections. Patients undergoing facial filler injections almost always have the same type of injection performed bilaterally in order to maintain symmetry. This provides a unique opportunity where participants can serve as their own controls. Participants will be injected with HA on half of their face and the other half of the face will be injected with HA+TXA. Swelling, bruising, pain, and overall satisfaction will be assessed using participant self-reported surveys, physician surveys, and review of medical records.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HA will be diluted with TXA using a Leur-Lok hub in a ratio of 1.0 mL HA filler to 0.2 mL TXA (100mg/mL)
Drug: Tranexamic acid · Drug: Hyaluronic acid
HA will be diluted with saline in a ratio of 1.0 mL HA filler to 0.2 mL saline
Other: Saline · Drug: Hyaluronic acid
TXA is a synthetic lysine analogue that inhibits the activation of plasminogen to plasmin, thus inhibiting degradation of fibrin clots and serving as an antifibrinolytic
Also known as: TXA
sodium chloride and water for use as control
Hyaluronidase is a spreading or diffusing substance which modifies the permeability of connective tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue
Also known as: HA, Hyaluronidase
Intensity of Bruising Score
Participant reported intensity of bruising score on a 5 point Likert scale where 1 is no bruising and 5 is severe bruising.
Time frame: Post procedure day 7
Intensity of Bruising Score
Participant reported intensity of bruising score on a 5 point Likert scale where 1 is no bruising and 5 is severe bruising.
Time frame: Post procedure day 1
Intensity of Bruising Score
Participant reported intensity of bruising score on a 5 point Likert scale where 1 is no bruising and 5 is severe bruising.
Time frame: Post procedure day 30
Intensity of Swelling Score
Participant reported intensity of swelling score on a 5 point Likert scale where 1 is no swelling and 5 is severe swelling.
Time frame: Post procedure day 1
Intensity of Swelling Score
Participant reported intensity of swelling score on a 5 point Likert scale where 1 is no swelling and 5 is severe swelling.
Time frame: Post procedure day 7
Intensity of Swelling Score
Participant reported intensity of swelling score on a 5 point Likert scale where 1 is no swelling and 5 is severe swelling.
Time frame: Post procedure day 30
Pain Score
Participants will rate their pain on a scale of 0-10 where 0 is no pain and 10 is the highest pain.
Time frame: Post procedure day 1
Pain Score
Participants will rate their pain on a scale of 0-10 where 0 is no pain and 10 is the highest pain.
Time frame: Post procedure day 7
Pain Score
Participants will rate their pain on a scale of 0-10 where 0 is no pain and 10 is the highest pain.
Time frame: Post procedure day 30
Participant Satisfaction Score
Participants will rate their satisfaction on a 5 point Likert scale where 1 is completely dissatisfied and 5 is completely satisfied.
Time frame: Post procedure day 1
Participant Satisfaction Score
Participants will rate their satisfaction on a 5 point Likert scale where 1 is completely dissatisfied and 5 is completely satisfied.
Time frame: Post procedure day 7
Participant Satisfaction Score
Participants will rate their satisfaction on a 5 point Likert scale where 1 is completely dissatisfied and 5 is completely satisfied.
Time frame: Post procedure day 30
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2022; primary completion for Jul 2023, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid
University of Wisconsin, Madison →